Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Recruiting 9Completed 7Active not recruiting 7Terminated 6Unknown 5Not yet recruiting 4Withdrawn 1

Sponsor Class

OTHER 4

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Thoracic 4

Conditions

Neoadjuvant Non-Small Cell Lung Cancer 1NSCLC 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 122Carboplatin 120Drug Therapy 104Bevacizumab 101Capecitabine 96Oxaliplatin 95Radiotherapy 92Gemcitabine 88Paclitaxel 87tislelizumab 84Cyclophosphamide 83Specimen Handling 80pembrolizumab 76toripalimab 66Magnetic Resonance Spectroscopy 63Fluorouracil 61sintilimab 58Injections 57anlotinib 51Docetaxel 51Surgical Procedures, Operative 48130-nm albumin-bound paclitaxel 48fludarabine 45Pemetrexed 43Standard of Care 42Biopsy 42venetoclax 41Irinotecan 41lenvatinib 40Leucovorin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × lorlatinib × Clear all
NCT07083687 2025-07-24

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Hunan Cancer Hospital

Phase 2 Not yet recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06893354 2025-03-25

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

The First Affiliated Hospital of Guangzhou Medical University

Phase 4 Not yet recruiting
20 enrolled
Thoracic

NSCLC

NCT06858410 2025-03-05

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Guangdong Association of Clinical Trials

Phase 3 Not yet recruiting
36 enrolled
Thoracic

Adenocarcinoma of Lung

NCT06682884 2024-11-12

NEOLORA

Peking University People's Hospital

Phase 2 Not yet recruiting
25 enrolled
Thoracic

Neoadjuvant Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡